Development of a polygenic score predicting drug resistance and patient outcome in breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers identified 36 genes linked to anti-cancer drug resistance. A derived polygenic score, UAB36, accurately predicted patient survival and drug resistance, outperforming existing biomarkers.
Area Of Science
- Genomics
- Cancer Biology
- Pharmacogenomics
Background
- Drug resistance is a major challenge in cancer therapy.
- Identifying predictive biomarkers for drug response is crucial for personalized medicine.
Purpose Of The Study
- To identify genes associated with cancer cell drug resistance.
- To develop and validate a polygenic score for predicting treatment outcomes.
Main Methods
- Analysis of gene expression profiles and drug response data from large cancer cell line datasets (GDSC and CTRP).
- Development of a polygenic score (UAB36) based on 36 identified genes.
- Validation of UAB36 in predicting Tamoxifen resistance and patient survival in independent breast cancer cohorts.
Main Results
- Expression of 36 genes correlated with drug resistance across two large cell line datasets.
- The UAB36 polygenic score accurately predicted cell line resistance to Tamoxifen.
- UAB36 demonstrated superior prediction of breast cancer patient survival compared to existing gene signatures and clinical covariates.
Conclusions
- A 36-gene signature can predict drug resistance in cancer cell lines.
- The UAB36 polygenic score is a robust predictor of Tamoxifen response and patient outcome in breast cancer.
- This approach offers potential for developing novel polygenic biomarkers for various cancer types and drugs.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...